Background
==========

Avascular necrosis of the femoral head (ANFH) is considered to be part of a multifactorial, heterogeneous group of disorders that lead to the necrosis and collapse of the femoral head during later stages \[[@b1-medscimonit-20-2811]--[@b3-medscimonit-20-2811]\]. ANFH may induce hip joint dysfunction and partial or complete loss of the ability to walk \[[@b4-medscimonit-20-2811]\]. ANFH can be caused by various conditions such as trauma, glucocorticoid (GC) therapy, alcoholism \[[@b5-medscimonit-20-2811]\], and storage diseases, of which GC-induced ANFH (GANFH) ranks first. The exact pathogenesis of femoral head osteonecrosis related to GC remains uncertain. There are several alternative mechanisms such as fat embolization \[[@b6-medscimonit-20-2811]\], intramedullary pressure changes \[[@b7-medscimonit-20-2811]\], modified artery constriction \[[@b8-medscimonit-20-2811],[@b9-medscimonit-20-2811]\], circulatory impairment \[[@b10-medscimonit-20-2811]\], coagulation disorders \[[@b11-medscimonit-20-2811]\], and cell dysfunction \[[@b12-medscimonit-20-2811],[@b13-medscimonit-20-2811]\]; however, none alone can explain the underlying mechanism. Moreover, it cannot be ignored that while some people develop osteonecrosis others do not under the same conditions. This phenomenon suggests that individual susceptibility or individual genetic factors may exist. It was recently suggested that genetic polymorphisms of the enzymes responsible for steroid metabolism, steroid receptors, and transport proteins may explain the individual differences \[[@b14-medscimonit-20-2811],[@b15-medscimonit-20-2811]\].

The transport protein, P-glycoprotein (P-gp), which acts as an energy-dependent membrane efflux pump for a wide spectrum of therapeutic agents, including steroids, plays an important role in absorption and distribution of drugs. P-gp is encoded by the multidrug resistance gene 1 (ABCB1), also known as MDR1. The ABCB1 gene is locked on chromosomal region 7q21 and consists of 28 exons. More than 50 single-nucleotide polymorphisms (SNPs) of MDR1 have been identified, among which single-nucleotide polymorphisms in exon 21 (G2677T/A, rs2032582) and exon 26 (C3435T, rs1045642) are the most studied. Particularly, rs2032582 and rs1045642 SNPs have been found to be related with a decreased and an increased expression of P-gp, respectively \[[@b16-medscimonit-20-2811]\]. However, controversy continues in clinical research. Takeshi Asano et al. \[[@b17-medscimonit-20-2811]\] demonstrated the ABCB1 rs1045642 and rs2032582 polymorphism decreased the risk for GANFH after kidney transplantation. Similar results were found based on patients with systemic lupus erythematosus \[[@b18-medscimonit-20-2811]\]. However, others demonstrated patients carrying rs2032582rs2032582 polymorphism had a higher risk of developing GANFH than those with wild-type genotypes \[[@b14-medscimonit-20-2811]\]. Also, no significant differences were found between patients with or without rs1045642 polymorphism. Recently, another study found rs1045642 polymorphism may decrease the risk of having GANFH, but there was no relationship between the rs2032582 polymorphism and GANFH \[[@b19-medscimonit-20-2811]\]. Even more, another study showed that rs1045642 polymorphism may be a risk factor for susceptibility to GANFH \[[@b20-medscimonit-20-2811]\].

Thus, the aim of this study was to assess the association of the ABCB1 gene polymorphisms with the risk of GANFH by conducting a meta-analysis of eligible studies published to date.

Material and Methods
====================

The PubMed, Cochrane Library, and Embase databases were searched independently by 2 investigators to retrieve relevant studies published before May 30, 2014. The search criteria "ABCB1", "ATP binding cassette B1", "multidrug resistance gene 1", "MDR1", and "osteonecrosis" were used in text word searches. The "related articles" function was used to broaden the search. The reference lists of the selected articles were also manually examined to find relevant studies not discovered during the database searches.

We selected any studies that investigated the relationship between ABCB1 polymorphism (rs1045642 and rs2032582) and GANFH susceptibility. All titles, abstracts, and full papers of potentially relevant studies were assessed for eligibility. When several reports from the same study were published, only the most recent or informative one was included in this meta-analysis. The language was restricted to only English.

Data extraction
---------------

The data extraction of all variables and outcomes of interest were performed independently by 2 investigators. Disagreements were resolved through discussion and consensus. Data on clinical design, country of study, number of participants, and genotyping information were extracted. If articles reported insufficient data, we contacted corresponding authors for additional information.

Quality assessment
------------------

The included studies were assessed independently by the 2 reviewers using the Newcastle-Ottawa Scale (NOS) \[[@b21-medscimonit-20-2811],[@b22-medscimonit-20-2811]\]. The NOS employs a star rating system to assess quality from 3 broad perspectives of the study: (1) selection of the study groups, (2) comparability of the groups, and (3) identification of the exposure (for case-control studies) or outcome of interest (for cohort studies). Scores ranged from 0 to 9 stars, and studies with no less than 7 stars were considered to be of high quality.

Statistical analysis
--------------------

The statistical analysis was performed using meta-analysis software called "Comprehensive Meta Analysis". The strength of the association between gene polymorphisms and GANFH risk was calculated with the OR and respective 95% CIs. The significance of the pooled OR was determined by the Z test, and P-values of less than 0.05 were considered significant. Chi-square test was used for the Hardy-Weinberg equilibrium (HWE) of genotypes in the control group of each study. Statistical heterogeneity among studies was assessed with the I^2^ statistics, which ranges from 0% (complete consistency) to 100% (complete inconsistency). If the I^2^ -value was more than 50%, the random-effects model was chosen to calculate the pooled OR; otherwise the fixed-effects model was used. All of the results were presented as forest plots. In the sensitivity analysis, we removed each particular study and performed meta-analysis with the rest repeatedly to show how conclusions might be affected. The presence of publication bias was assessed by a visual inspection of a funnel plot and Egger's linear regression test.

Results
=======

Literature Search
-----------------

The initial literature search retrieved 22 relevant articles (duplicates were discarded) and 7 articles were excluded for not investigating the topic after carefully screening the titles and abstracts. Then, full publication review was performed, and 2 articles were excluded (1 study of overlapping data, and 1 cell study), which left 5 studies (all case-control studies) for this meta-analysis \[[@b14-medscimonit-20-2811],[@b17-medscimonit-20-2811]--[@b20-medscimonit-20-2811]\]. Flowcharts describing the study selection are shown in [Figure 1](#f1-medscimonit-20-2811){ref-type="fig"}. All included studies were in accordance with the NOS scale and were therefore defined as high-quality studies.

A total of 833 patients (281 with GANFH and 552 controls) were enrolled in the studies. The key characteristics of the included studies are summarized in [Table 1](#t1-medscimonit-20-2811){ref-type="table"}. A review of the data extraction revealed 100% agreement between the 2 reviewers.

Main analysis
-------------

[Table 2](#t2-medscimonit-20-2811){ref-type="table"} lists the main results of the meta-analysis for the relationship between gene ABCB1 polymorphism and GANFH.

For rs1045642 polymorphism, quantitative synthesis from 5 studies showed significant differences in the comparisons of CC *vs.* CT+TT (Case *vs.* Control, OR, 1.462; 95% CI, 1.066--2.007; P=0.019). However, no significant differences were found when comparing CC *vs.* CT, CC *vs.* TT, or CT *vs.* TT ([Figure 2](#f2-medscimonit-20-2811){ref-type="fig"}).

For rs2032582 polymorphism, the frequencies of G(TA) and (TA)(TA) in the Wei He et al. \[[@b14-medscimonit-20-2811]\] study control groups were zero; hence, the study was excluded when we conducted meta-analysis for comparison of the G(TA) and (TA)(TA). Quantitative synthesis showed significant differences in the comparisons of GG *vs.* G(TA)+(TA)(TA) (Case *vs.* Control, OR, 1.548; 95% CI,1.063--2.255; P=0.023). However, no significant difference was found when comparing GG *vs.* G(TA), GG *vs.* (TA)(TA), or G(TA) *vs.* (TA)(TA) ([Figure 3](#f3-medscimonit-20-2811){ref-type="fig"})

In the sensitivity analysis, when each particular study was removed from analysis, no corresponding pooled ORs were qualitatively altered.

Publication bias
----------------

Funnel plots and Egger's test were performed to assess the publication bias of studies included in this meta-analysis. The funnel plots and Egger's test demonstrated no evidence of publication bias for CC *vs.* CT+TT (P=0.40) or GG *vs.* G(TA)+(TA)(TA) (P=0.17) ([Figure 4](#f4-medscimonit-20-2811){ref-type="fig"}).

Discussion
==========

The most important finding of this study was that the ABCB1 polymorphisms (rs1045642 and rs2032582) were found to significantly decrease GANFH susceptibility.

It is well known that glucocorticoids may induce a hypercoagulable hypofibrinolysis state in blood, which may induce thrombosis of the vessels, resulting in bone ischemia, necrosis of bone tissue, and, finally, ANFH occurs. However, the truth is that not all patients treated with virtually the same protocol for steroid administration develop ANFH, which means the individual differences in the steroid sensitivity (ability to absorb and metabolize glucocorticoids) due to genetic factors play an important role in the development of GANFH. Recently, studies found that polymorphisms of the molecules involved in steroid metabolism, steroid receptors, or drug transport may be involved in this individual difference.

The membrane transporter protein P-gp, encoded by the human ABCB1 gene, is an important determinant in drug absorption, distribution, and elimination \[[@b23-medscimonit-20-2811]\]. The ABCB1 polymorphisms have been demonstrated to affect the expression and function of P-gp and therefore determine individual variability in drug resistance. Several case-control studies have examined the association between the ABCB1 polymorphisms and steroid-induced ONFH \[[@b17-medscimonit-20-2811],[@b18-medscimonit-20-2811],[@b24-medscimonit-20-2811]\]. However, as discussed above, reports concerning the role of the polymorphisms in the pathogenesis of GANFH have been inconsistent. The lack of consistency across these studies may be caused by the geographic and ethnic variability of populations or the probability of a type II error resulting from small sample sizes. Thus, this meta-analysis was performed to overcome the weakness in sample size and population.

The mechanism by which these 2 SNPs decrease the risk of GANFH is still unknown. Rs2032582 of ABCB1 was recently reported to be associated with an amino acid substitution (Ala^893^ to Ser^893^ and Ala^893^ to Thr^893^), leading to an enhanced efflux transporting ability, and, finally, decreased risk of GANFH \[[@b25-medscimonit-20-2811]\]. Rs1045642 SNP present in exon 26 was considered as a functional SNP, and its relationship with various diseases has been reported \[[@b26-medscimonit-20-2811]--[@b28-medscimonit-20-2811]\]. Rs1045642 SNP is a synonymous polymorphism that does not change the protein sequence, but it affects RNA stability and alters the interaction of P-gp with drugs by affecting the timing of co-translational folding \[[@b29-medscimonit-20-2811],[@b30-medscimonit-20-2811]\]; thus, the rs1045642 SNP may decrease the amount and activity of P-gp. It is interesting that the results showed a negative association between rs1045642 and GANFH susceptibility. An explanation may be the linkage disequilibrium between rs1045642 and rs2032582, as reported in various studies \[[@b18-medscimonit-20-2811],[@b19-medscimonit-20-2811]\].

The most important limitation of this meta-analysis is the inconsistency of the baseline characteristics (e.g., age, sex, and concomitant disease) between the case and control groups, which might increase the selection bias.

Conclusions
===========

The results of this meta-analysis suggest that the ABCB1 polymorphisms (rs1045642 and rs2032582) significantly decrease GANFH susceptibility.
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###### 

Characteristics of the included studies.

  Author           Year   Country   Patients                                Groups   ABCB1 genotype                                                                        
  ---------------- ------ --------- --------------------------------------- -------- ---------------- ---- ---- ---- ---- ---- ---- ------- ---- ---- ---- ---- ----- ---- -------
  Takeshi Asanoa   2003   Japan     After Kidney Transplantation            30       106              12   17   1    34   49   23   0.501   9    17   4    21   50    35   0.682
  X. Y. Yang       2007   China     Systemic lupus erythematosus patients   21       106              11   9    1    39   45   22   0.186   10   10   1    30   57    19   0.369
  Wei He           2009   China     With corticosteroid therapy             31       17               24   7    0    14   3    0    0.69    18   13   0    17   0     0    --
  Yanqiong Zhang   2014   China     With corticosteroid therapy             94       106              37   36   16   36   52   13   0.3     18   29   25   16   39    32   0.501
  Yun Xue          2014   China     With corticosteroid therapy             105      217              43   49   7    65   91   47   0.17    24   49   27   36   109   64   0.369

###### 

Pooled ORs and 95% CIs of stratified meta-analysis.

  Polymorphisms   Study count   Cases/controls   AA *vs.* Aa   AA *vs.* aa            AA *vs.* Aa+aa   Aa *vs.* aa                                                                                                                                      
  --------------- ------------- ---------------- ------------- ---------------------- ---------------- ------------- -------- ---------------------- ------- ------ ------- ---------------------- ------- ---- -------- ---------------------- ------- --------
  RS1045642       5             270/533          Fixed         1.248 (0.896, 1.738)   0.19             0             Random   2.859 (0.988, 8.273)   0.053   58.6   Fixed   1.462 (1.066, 2.007)   0.019   0    Random   2.381 (0.719, 7.883)   0.155   67.715
  RS2032582       5             254/525          Fixed         1.41 (0.948, 2.098)    0.09             35.4          Fixed    1.485 (0.908, 2.428)   0.115   46.7   Fixed   1.548 (1.063, 2.255)   0.023   41   Fixed    1.211 (0.807, 1.815)   0.355   20.6

For convenience, we considered the major allele in the variants as "A" and the minor as "a".
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